Citations |
Department of Biological Science. National Sun Yat-Sen University. 2015 Sep.<br/>Front Biosci-Landmrk. 2023 Oct 17, 28(10), 238.<br/>Lipids Health Dis. 2018 Jul 31;17(1):183. <br/>Neurobiol Dis. 2014 Nov;71:292-304. <br/>Department of Pharmaceutical Sciences. East Tennessee State University. 2015 May.<br/>Drug Metab Pharmacokinet. 2024 Mar 11, 101008.<br/>Toxicology Research and Application. September 25, 2018.<br/>Toxicology Research and Application. 2018, 2:239784731880115. <br/>[1]Yuji Nakamura, et al. Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor. ACS Med. Chem. Lett., 2012, 3 (9), pp 754–758<br/>[2]Buczko W, et al. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep. 2008 Sep-Oct;60(5):623-31.<br/>[3]Wood JM, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor.Biochem Biophys Res Commun, 2003, 308(4), 698-705.<br/>[4]Gradman AH, et al.Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation, 2005, 111(8), 1012-1018.<br/>[5]Chang AY, et al. Interplay between brain stem angiotensins and monocyte chemoattractant protein-1 as a novel mechanism for pressor response after ischemic stroke. Neurobiol Dis. 2014 Nov;71:292-304.<br/>[6]Wang C, et al. Aliskiren targets multiple systems to alleviate cancer cachexia. Oncol Rep. 2016 Nov;36(5):3014-3022. |
Product Description |
Aliskiren is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren can be used for the research of hypertension, cardiovascular diseases and cancer cachexia[1][2][3]. |